Assessment of C-X-C Motif Chemokine Ligand 10 (CXCL10) Serum Level in Patients with Vitiligo

Document Type : Original Article

Authors

1 Department of Dermatology, Ministry of Health and Population, Faqous General Hospital, El Sharqia, Egypt

2 Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Suez Canal University, Egypt.

3 Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Egypt

Abstract

Background: Vitiligo is a common depigmentation disorder that affects 0.1% to 2% of the population. Patients with vitiligo have an increase in autoreactive CD8+ T cells that target melanocytes in their serum and skin, resulting in melanocyte cytotoxicity.CXCL10 chemokine binds the CXCR3 receptor expressed on T cells, monocytes, and natural killer cells inducing their tissue recruitment.CXCL10 plays a role in many autoimmune diseases. Aim: Evaluate CXCL10 serum level in patients with vitiligocompared to healthy controls and detect its correlation with the disease activity.Methods:In this case-control study, 20 vitiligo patients and 20 healthy controls were enrolled. An enzyme-linked immunosorbent assay was used to compare the serum level of CXCL10 in vitiligo patients to healthy controls (ELISA).Results: The level of CXCL10serum was noticeably higher in patients with vitiligo than in controls (p=0.021) and correlated positively with disease activity (VIDA) (p < 0.001).Conclusion:CXCL10 might have a role in the pathogenesis of vitiligo and might serve as a marker for disease activity.Further large-scale studies are needed to confirm the definite role of CXCL10 in vitiligo pathogenesis.
 

Keywords

Main Subjects

Files

Share

How to cite

Statistics